OBJECTIVE: To evaluate the effect of surgical resection and radiotherapy (RT) in retroperitoneal or abdominal sarcoma. DESIGN: Retrospective cohort. SETTING: Surveillance, Epidemiology, and End Results, 1988-2005. PATIENTS: Patients 18 years or older with initial diagnosis of primary retroperitoneal and nonvisceral abdominal sarcoma. MAIN OUTCOME MEASURES: Survival for 2 years after diagnosis. Kaplan-Meier survival was stratified based on surgery and RT status. Cox proportional hazards model was used to assess adjusted effects of surgery and RT on survival in patients with locoregional disease. RESULTS: Of 1901 patients with locoregional disease, 1547 (81.8%) underwent resection; 447 (23.5%) received RT. Overall, patients who received both surgery and RT demonstrated improved survival compared with patients who underwent either therapy alone; patients undergoing monotherapy in turn had more favorable survival compared with patients who received neither therapy (P < .001, log rank). Cox analysis demonstrated that surgical resection (hazard ratio [HR], 0.24; 95% confidence interval [CI], 0.21-0.29; P < .001) and RT (0.78; 0.63-0.95; P = .01) independently predicted improved survival in locoregional disease only. In adjusted analyses stratified for American Joint Commission on Cancer (AJCC) stage, for stage I disease (n = 694), RT provided an additional benefit (HR, 0.49; 95% CI, 0.25-0.96; P = .04) independent of that from resection (0.35; 0.21-0.58; P < .001). For stage II/III (n = 552), resection remained protective (HR, 0.24; 95% CI, 0.18-0.32; P < .001); however, RT was no longer associated with a significant benefit (0.78; 0.58-1.06; P = .11). CONCLUSIONS: In a national cohort of retroperitoneal and abdominal sarcomas, surgical resection was associated with significant survival benefits for AJCC disease stages I to III. Radiotherapy provided additional benefit for patients with stage I disease. Resection should be offered to reasonable surgical candidates with nonmetastatic retroperitoneal/abdominal sarcomas; radiotherapy may most benefit patients with early-stage disease.
OBJECTIVE: To evaluate the effect of surgical resection and radiotherapy (RT) in retroperitoneal or abdominal sarcoma. DESIGN: Retrospective cohort. SETTING: Surveillance, Epidemiology, and End Results, 1988-2005. PATIENTS: Patients 18 years or older with initial diagnosis of primary retroperitoneal and nonvisceral abdominal sarcoma. MAIN OUTCOME MEASURES: Survival for 2 years after diagnosis. Kaplan-Meier survival was stratified based on surgery and RT status. Cox proportional hazards model was used to assess adjusted effects of surgery and RT on survival in patients with locoregional disease. RESULTS: Of 1901 patients with locoregional disease, 1547 (81.8%) underwent resection; 447 (23.5%) received RT. Overall, patients who received both surgery and RT demonstrated improved survival compared with patients who underwent either therapy alone; patients undergoing monotherapy in turn had more favorable survival compared with patients who received neither therapy (P < .001, log rank). Cox analysis demonstrated that surgical resection (hazard ratio [HR], 0.24; 95% confidence interval [CI], 0.21-0.29; P < .001) and RT (0.78; 0.63-0.95; P = .01) independently predicted improved survival in locoregional disease only. In adjusted analyses stratified for American Joint Commission on Cancer (AJCC) stage, for stage I disease (n = 694), RT provided an additional benefit (HR, 0.49; 95% CI, 0.25-0.96; P = .04) independent of that from resection (0.35; 0.21-0.58; P < .001). For stage II/III (n = 552), resection remained protective (HR, 0.24; 95% CI, 0.18-0.32; P < .001); however, RT was no longer associated with a significant benefit (0.78; 0.58-1.06; P = .11). CONCLUSIONS: In a national cohort of retroperitoneal and abdominal sarcomas, surgical resection was associated with significant survival benefits for AJCC disease stages I to III. Radiotherapy provided additional benefit for patients with stage I disease. Resection should be offered to reasonable surgical candidates with nonmetastatic retroperitoneal/abdominal sarcomas; radiotherapy may most benefit patients with early-stage disease.
Authors: Da-Xian Luo; Mei-Juan Huang; Bo Xiong; Tao Li; Ke Xie; Fu-Rong Chen; Guo-Wei Che; Jin Wang; Yong Xu; Xiao-Juan Zhou; You Lu Journal: Interact Cardiovasc Thorac Surg Date: 2013-09-11
Authors: Marco Milone; Luigi Sossio Pezzullo; Giuseppe Salvatore; Martina Gilda Pezzullo; Maddalena Leongito; Ida Esposito; Francesco Milone Journal: Updates Surg Date: 2011-04-01
Authors: Martin K Angele; Markus Albertsmeier; Niclas J Prix; Peter Hohenberger; Sultan Abdel-Rahman; Nelli Dieterle; Michael Schmidt; Ulrich Mansmann; Christiane J Bruns; Rolf D Issels; Karl-Walter Jauch; Lars H Lindner Journal: Ann Surg Date: 2014-11 Impact factor: 12.969
Authors: Daniel Y Joh; Gary D Kao; Surya Murty; Melissa Stangl; Lova Sun; Ajlan Al Zaki; Xiangsheng Xu; Stephen M Hahn; Andrew Tsourkas; Jay F Dorsey Journal: Transl Oncol Date: 2013-12-01 Impact factor: 4.243
Authors: B T Turner; L Hampton; D Schiller; L A Mack; C Robertson-More; H Li; M L Quan; A Bouchard-Fortier Journal: Curr Oncol Date: 2019-12-01 Impact factor: 3.677